2cureX AB (2CUREX) - Total Assets
Based on the latest financial reports, 2cureX AB (2CUREX) holds total assets worth Skr5.18 Million SEK (≈ $557.02K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of 2cureX AB to assess the company's total reinvestment commitment from operating cash flow.
2cureX AB - Total Assets Trend (2015–2024)
This chart illustrates how 2cureX AB's total assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of 2cureX AB to evaluate the tangible quality of the company's equity base.
2cureX AB - Asset Composition Analysis
Current Asset Composition (December 2024)
2cureX AB's total assets of Skr5.18 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 66.4% |
| Accounts Receivable | Skr2.56 Million | 33.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how 2cureX AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 2cureX AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 2cureX AB's current assets represent 100.0% of total assets in 2024, an increase from 92.1% in 2015.
- Cash Position: Cash and equivalents constituted 66.4% of total assets in 2024, up from 51.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 33.1% of total assets.
2cureX AB Competitors by Total Assets
Key competitors of 2cureX AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
2cureX AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.51 | 3.33 |
| Quick Ratio | 1.14 | 1.51 | 3.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr626.00K | Skr2.18 Million | Skr23.42 Million |
2cureX AB - Advanced Valuation Insights
This section examines the relationship between 2cureX AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 70.90 |
| Latest Market Cap to Assets Ratio | 0.67 |
| Asset Growth Rate (YoY) | -52.4% |
| Total Assets | Skr7.75 Million |
| Market Capitalization | $5.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values 2cureX AB's assets below their book value (0.67x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 2cureX AB's assets decreased by 52.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 2cureX AB (2015–2024)
The table below shows the annual total assets of 2cureX AB from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr7.75 Million ≈ $833.70K |
-52.41% |
| 2023-12-31 | Skr16.28 Million ≈ $1.75 Million |
-65.84% |
| 2022-12-31 | Skr47.66 Million ≈ $5.13 Million |
-39.80% |
| 2021-12-31 | Skr79.16 Million ≈ $8.52 Million |
+25.56% |
| 2020-12-31 | Skr63.04 Million ≈ $6.78 Million |
+66.60% |
| 2019-12-31 | Skr37.84 Million ≈ $4.07 Million |
+57.50% |
| 2018-12-31 | Skr24.03 Million ≈ $2.59 Million |
+5.17% |
| 2017-12-31 | Skr22.85 Million ≈ $2.46 Million |
+110.72% |
| 2016-12-31 | Skr10.84 Million ≈ $1.17 Million |
-10.15% |
| 2015-12-31 | Skr12.07 Million ≈ $1.30 Million |
-- |
About 2cureX AB
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.